TScan Therapeutics, Inc. (NASDAQ:TCRX) is among the top 10 stocks under $5 that could triple.
A dose bottle of the medication is in the medical tech’s hand
As of March 19, 2026, analysts maintain a strong sentiment regarding TScan Therapeutics, Inc. (TCRX). With over 80% of analysts holding a “Buy” rating, the stock is projected to have a 455.56% potential upside based on the consensus price target.
Developments regarding TScan Therapeutics, Inc.’s pipeline have helped strengthen the confidence of analysts at Wedbush amid ongoing momentum in the cell therapy space.
A broader update is scheduled for the second half of 2026, with the firm highlighting data from its Phase 1 ALLOHA trial’s Cohort C, which is expected in Q2 2026. Wedbush noted that upcoming conferences like ASH and EHA will likely serve as occasions for these updates, further adding that the company’s near-term outlook will hinge on these developments.
On March 5, 2026, Wedbush reiterated its “Outperform” rating and increased its price target for TScan Therapeutics, Inc. from $4 to $5. Analysts emphasized the company’s continuous development, especially as it expands its clinical programs.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T-cell receptor therapies aimed at malignancies and other serious diseases, utilizing its platform to discover novel antigens and reduce off-target interactions.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
